Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R K Desser

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Annals of Internal Medicine|July 1, 1972
Risk of severe infection in patients with Hodgkin's disease or lymphoma after diagnostic laparotomy and splenectomyR K Desser, J E Ultmann
Series Haematologica (1968)|January 1, 1973
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singlyR K Desser, J E Ultmann
Lancet (London, England)|January 31, 1976
Letter: Combined therapy for small-cell carcinoma of the bronchusJ Bitran, H M Golomb, R K Desser
Cancer|April 1, 1980
The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancerJ D Bitran, C Bekerman, R K Desser
The Medical Clinics of North America|March 1, 1973
Staging of Hodgkin's disease and lymphoma. Diagnostic procedures including staging laparotomy and splenectomyR K Desser, E M Moran, J E Ultmann
Cancer Investigation|January 1, 1990
Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II studyJ D Bitran, M F Kozloff, R K Desser
Rational Drug Therapy|February 1, 1974
Drug therapy in Hodgkin's diseaseE M Moran, R K Desser, J E Ultmann
Cancer Treatment Reports|March 1, 1976
Letter: Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC-26271), vincristine (NSC-67574), and methotrexate (NSC-7040)J Bitran, H M Golomb, R K Desser, et al.
Blood|November 1, 1980
Successful management of bleeding in a patient with factor V inhibitor by platelet transfusionsJ Chediak, J B Ashenhurst, I Garlick, et al.
JAMA|December 15, 1978
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)J D Bitran, R K Desser, T DeMeester, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Annals of Internal Medicine|July 1, 1972
Risk of severe infection in patients with Hodgkin's disease or lymphoma after diagnostic laparotomy and splenectomyR K Desser, J E Ultmann
Series Haematologica (1968)|January 1, 1973
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singlyR K Desser, J E Ultmann
Lancet (London, England)|January 31, 1976
Letter: Combined therapy for small-cell carcinoma of the bronchusJ Bitran, H M Golomb, R K Desser
Cancer|April 1, 1980
The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancerJ D Bitran, C Bekerman, R K Desser
The Medical Clinics of North America|March 1, 1973
Staging of Hodgkin's disease and lymphoma. Diagnostic procedures including staging laparotomy and splenectomyR K Desser, E M Moran, J E Ultmann
Cancer Investigation|January 1, 1990
Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II studyJ D Bitran, M F Kozloff, R K Desser
Rational Drug Therapy|February 1, 1974
Drug therapy in Hodgkin's diseaseE M Moran, R K Desser, J E Ultmann
Cancer Treatment Reports|March 1, 1976
Letter: Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC-26271), vincristine (NSC-67574), and methotrexate (NSC-7040)J Bitran, H M Golomb, R K Desser, et al.
Blood|November 1, 1980
Successful management of bleeding in a patient with factor V inhibitor by platelet transfusionsJ Chediak, J B Ashenhurst, I Garlick, et al.
JAMA|December 15, 1978
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)J D Bitran, R K Desser, T DeMeester, et al.
Pageof 4